Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Natera, Inc.
  6. Summary
    NTRA   US6323071042

NATERA, INC.

(NTRA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/20/2021 09/21/2021 09/22/2021 09/23/2021 09/24/2021 Date
119.68(c) 123.7(c) 125.68(c) 123.54(c) 118.12(c) Last
700 836 624 565 475 012 624 865 774 552 Volume
-5.29% +3.36% +1.60% -1.70% -4.39% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 615 M - -
Net income 2021 -417 M - -
Net cash position 2021 563 M - -
P/E ratio 2021 -25,4x
Yield 2021 -
Sales 2022 753 M - -
Net income 2022 -418 M - -
Net cash position 2022 267 M - -
P/E ratio 2022 -26,3x
Yield 2022 -
Capitalization 11 078 M 11 078 M -
EV / Sales 2021 17,1x
EV / Sales 2022 14,4x
Nbr of Employees 1 815
Free-Float 96,3%
More Financials
Company
Natera, Inc. is a diagnostics company. The Company is engaged in the discovery, development and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's... 
More about the company
Ratings of Natera, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about NATERA, INC.
09/20Certain Restricted Stock Units of Natera, Inc. are subject to a Lock-Up Agreement Endi..
CI
09/20Certain Options of Natera, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-202..
CI
09/20Certain Common Stock of Natera, Inc. are subject to a Lock-Up Agreement Ending on 20-SE..
CI
09/17NATERA : Releases New Clinical Data at ESMO 2021 in Gastroesophageal Cancer and Uveal Mela..
PR
09/17Natera, Inc. Releases New Clinical Data at ESMO 2021 in Gastroesophageal Cancer and Uve..
CI
09/13INSIDER SELL : Natera
MT
09/09Natera, Inc. Launches ProsperaÖ Kidney with Quantification to Further Improve Test Perf..
CI
09/07NATERA : Signatera« Test Selected for NRG Oncology's Landmark CIRCULATE-US Study of MRD-Gu..
PR
09/07Natera's Signatera Test Selected for NRG Oncology's Landmark CIRCULATE-US Study of MRD-..
CI
08/31NATERA : Announces the Validation and Launch of the Prospera™ Heart Transplant Asses..
PR
08/31Natera Announces the Validation and Launch of the ProsperaÖ Heart Transplant Assessment..
CI
08/26NATURALLY SPLENDID ENTERPRISES : Says Denny's Restaurants to Offer Its Natera Plant-Based ..
MT
08/10NATERA : to Participate in Upcoming Investor Conferences
PR
08/09NATERA : Piper Sandler Adjusts Natera's Price Target to $160 From $155, Maintains Overweig..
MT
08/06NATERA : BTIG Adjusts Natera's Price Target to $160 From $155, Maintains Buy Rating
MT
More news
News in other languages on NATERA, INC.
07/13LES MARCHÉS EN VACANCES : Emission du 13 juillet 2021
02/18NATERA : y Personalis se unen para garantizar un seguimiento personalizado en oncología
02/18NATERA : und Personalis kooperieren im Bereich der personalisierten Überwachung in der Onk..
02/17NATERA : en Personalis werken samen voor gepersonaliseerde monitoring in oncologie
02/17NATERA : e Personalis stringono una collaborazione per il monitoraggio personalizzato nel ..
More news
Analyst Recommendations on NATERA, INC.
More recommendations
Chart NATERA, INC.
Duration : Period :
Natera, Inc. Technical Analysis Chart | NTRA | US6323071042 | MarketScreener
Technical analysis trends NATERA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 118,12 $
Average target price 150,13 $
Spread / Average Target 27,1%
EPS Revisions
Managers and Directors
Stephen Chapman President, Chief Executive Officer & Director
Michael Burkes Brophy Chief Financial Officer
Matthew Rabinowitz Executive Chairman
Paul R. Billings Chief Medical Officer & Senior VP-Medical Affairs
Eric A. Evans Chief Scientific Officer
Sector and Competitors